Selectively Sensitizing Malignant Cells to Photothermal Therapy Using a CD44-Targeting Heat Shock Protein 72

Shouju Wang1,2, Ying Tian1,2, Wei Tian1

  • 1Department of Medical Imaging, Jinling Hospital, School of Medicine, Nanjing University , Nanjing 210002, P.R. China.

ACS Nano
|August 31, 2016
PubMed

Insights

This study developed a novel nanosystem to target triple-negative breast cancer (TNBC) cells. The system enhances photothermal therapy (PTT) efficacy by targeting CD44 and depleting heat shock protein 72 (HSP72), improving treatment accuracy.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cancer Therapy

Background:

  • Photothermal therapy (PTT) faces challenges in selectively targeting solid tumors like triple-negative breast cancer (TNBC) due to a lack of distinct surface markers.
  • Overexpressed surface molecules (CD44) and malignancy-specific chaperones (heat shock protein 72, HSP72) present potential targets for selective cancer treatment.

Purpose of the Study:

  • To develop a targeted nanosystem for selective sensitization of TNBC to PTT.
  • To investigate the combined targeting of CD44 and depletion of HSP72 for enhanced PTT efficacy and accuracy.

Main Methods:

  • A layer-by-layer method was used to construct a gold nanostar (GNS)/siRNA against HSP72 (siHSP72)/hyaluronic acid (HA) nanosystem.
  • Characterization included hydrodynamic diameter, zeta potential, CD44-targeting confirmation (flow cytometry, confocal microscopy), and HSP72 silencing efficacy assessment.
  • In vitro and in vivo studies evaluated the therapeutic efficacy and side effects of the nanosystem in TNBC models.

Main Results:

  • The GNS/siHSP72/HA nanosystem exhibited a particle size of 73.2 ± 3.8 nm and a negative surface charge.
  • Confirmed CD44-targeting ability and achieved approximately 95% HSP72 silencing efficacy.
  • Demonstrated selective sensitization of TNBC cells to hyperthermia, enhancing therapeutic efficacy with minimal side effects both in vitro and in vivo.

Conclusions:

  • The rationally designed GNS/siHSP72/HA nanosystem effectively targets CD44 and depletes HSP72 in TNBC.
  • This sequential targeting approach selectively sensitizes TNBC to PTT, improving treatment accuracy and minimizing side effects.
  • The nanosystem offers advantages including easy synthesis, high siRNA loading, endosomal escape, efficient photothermal conversion, and good biocompatibility.